Clinical trials: Bladder Cancers
Urothelial Carcinoma
An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma
This is a multicenter, open-label, randomized, Phase 2 umbrella study of various neoadjuvant treatment combinations in participants who have muscle-invasive urothelial carcinoma of the bladder and are cisplatin-ineligible or…
- Trial name
- Optimus (NCT04586244)
- Testing
- retifanlimab, epacadostat, INCAGN02385
- Where
- 12 sites in United States, France and 1 more
- Volunteers
- 30 people
- Sponsor
- Incyte Corporation
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Ann Arbor Stage I Lymphoma, Ann Arbor Stage II Lymphoma
- Trial name
- NCT05334069
- Testing
- Questionnaire Administration, Biospecimen Collection
- Where
- 751 sites in United States
- Volunteers
- 2,900 people, healthy volunteers welcome
- Sponsor
- Alliance for Clinical Trials in Oncology
Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477)
This study will test how well Regorafenib controls disease progression in urothelial cancer (cancer occurring in the urinary bladder, ureters, or renal pelvis) following previous therapy with chemotherapy.
- Trial name
- NCT02459119
- Testing
- Regorafenib
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- University of Alabama at Birmingham
Muscle Invasive Bladder Cancer
Effect of Neoadjuvant Chemotherapy on MRI Accuracy Before Cystectomy
The goal of this clinical trial is to learn if neoadjuvant chemotherapy (NAC) affects the accuracy of magnetic resonance imaging (MRI) in staging muscle-invasive bladder cancer (MIBC).
- Trial name
- "NAC-MRI" (NCT07202819)
- Testing
- Neoadjuvant Chemotherapy, Radical Cystectomy
- Where
- 2 sites in Egypt
- Volunteers
- 76 people
- Sponsor
- Assiut University
Bladder Cancer, Benign Prostatic Hyperplasia
Intravesical Prostatic Protrusion Mimicking Urothelial Cell Carcinoma of the Bladder
In this study, investigators aim to determine the true positivity of bladder cancer identified in the bladder base, trigone or neck on ultrasonography (USG) in patients presenting with hematuria or lower urinary tract symptoms…
- Conditions
- Bladder Cancer, Benign Prostatic Hyperplasia, Hematuria
- Trial name
- NCT05077852
- Testing
- Urethrocystoscopy
- Where
- Turkey (Türkiye)
- Volunteers
- 194 people
- Sponsor
- Ankara Training and Research Hospital
Urothelial Carcinoma Bladder, Bladder Cancer
Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer
The primary objective of this Phase I study is to establish the safety of adjuvant concurrent immunotherapy and radiation therapy for urothelial bladder cancer.
- Trial name
- NCT06586255
- Testing
- Concurrent Immunotherapy and Radiation Therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Kidney Cancer, Prostate Cancer
A Prospective Study of Clinical Factors Affecting Disease Progression and Treatment Results of Patients With Tumors of the Prostate, Bladder and Kidney.
Identifying clinical factors such as medication, background diseases and blood tests that effect the course of disease in cancer patients can help physicians to better decide on the patient's treatment plan.
- Conditions
- Kidney Cancer, Prostate Cancer, Bladder Cancer
- Trial name
- NCT02186925
- Where
- Israel
- Volunteers
- 1,000 people
- Sponsor
- Meir Medical Center
Non-Invasive Papillary Carcinoma of Bladder
ONCOFID-P-B in the Intravescical Therapy of Patients With Non-muscle Invasive Cancer of the Bladder.
The purpose of the study is to assess, at control visit (V8), the ablative activity of intravesical administration of Oncofid-P-B on a papillary marker tumor on patients suffering from multiple primary and recurrent Ta G1-G2…
- Trial name
- NCT04661826
- Testing
- Oncofid-P-B
- Where
- 14 sites in Germany, Italy and 1 more
- Volunteers
- 60 people
- Sponsor
- Fidia Farmaceutici s.p.a.
Urothelial Carcinoma Bladder
Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy
Currently, the standard of care for female patients undergoing radical cystectomy includes the removal of the bladder, pelvic lymph nodes, anterior vagina, uterus, fallopian tubes and ovaries.
- Trial name
- NCT06184516
- Testing
- Reproductive organ sparing radical cystectomy, Radical cystectomy
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- University of Florida
Solid Tumors
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
This is a Phase 1, open-label, dose-escalation trial of avelumab [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in participants with selected tumor indications.
- Trial name
- NCT01772004
- Testing
- Avelumab
- Where
- 74 sites in United States, Belgium and 7 more
- Volunteers
- 1,756 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Bladder Neoplasms, Carcinoma, Transitional Cell
A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder
Patients with superficial transitional cell carcinoma of the bladder will be treated with intravesical suramin in a phase I dose escalating study. The toxicity of suramin administered in this fashion will be evaluated.
- Trial name
- NCT00001381
- Testing
- suramin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer
Fluorescence Cystoscopy and Optimized MMC in Recurrent Bladder Cancer (FinnBladder 9)
Bladder cancer (BC), the second most common urological malignancy, is an important public health issue. One of the main challenges in the treatment of bladder cancer if the prevention of recurrences of non-invasive tumors, which…
- Trial name
- NCT01675219
- Testing
- white light TUR-BT, blue light TUR-BT, optimized MMC
- Where
- 10 sites in Finland
- Volunteers
- 400 people
- Sponsor
- Turku University Hospital
Quadratus Lumborum Block, Transversus Abdominis Plane Block
Quadratus Lumborum Block vs Transversus Abdominis Plane Block in Bladder Cancer Surgeries
Transversus abdominis plane (TAP) block can be used to provide effective analgesia during the postoperative period following a range of surgeries.
- Conditions
- Quadratus Lumborum Block, Transversus Abdominis Plane Block, Bladder Cancer, Postoperative Pain
- Trial name
- NCT04402411
- Testing
- Quadratus lumborum block, Transversus abdominis plane block, Intravenous opioid
- Where
- Egypt
- Volunteers
- 63 people
- Sponsor
- National Cancer Institute, Egypt
Febrile Neutropenia, Cancer
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
This international, prospective, observational, open-label, pharmaco-epidemiologic study observes cancer patients at risk for chemotherapy-induced febrile neutropenia (FN) who are receiving filgrastim biosimilar (EP2006) for…
- Conditions
- Febrile Neutropenia, Cancer, Breast Cancer, Ovarian Cancer
- Trial name
- Monitor-GCSF (NCT01459653)
- Where
- 117 sites in Austria, Belgium and 10 more
- Volunteers
- 1,496 people
- Sponsor
- Sandoz
Urinary Bladder Cancer, Invasive Bladder Cancer
A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study
A multicenter Phase 1b/2, two stage, open label study of MMC/Capecitabine ChRT combined with nivolumab monotherapy or nivolumab and ipilimumab combination therapy in adult (>18 years) subjects with non-metastatic muscle invasive…
- Trial name
- CRIMI (NCT03844256)
- Testing
- nivolumab 480mg, nivolumab 3mg/kg, ipilimumab 1mg/kg, nivolumab 1mg/kg, ipilimumab 3mg/kg
- Where
- 3 sites in Netherlands
- Volunteers
- 50 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Advanced Solid Cancers
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
The main goal of this study is to evaluate the safety of BNT329 and to identify the best dose of BNT329. This will be done by measuring the number of side effects that participants experience and how severe they are.
- Trial name
- NCT07186842
- Testing
- BNT329, CA19-9-targeting monoclonal antibody
- Where
- 18 sites in United States, Australia and 3 more
- Volunteers
- 245 people
- Sponsor
- BioNTech SE
Bladder Cancer
Microsatellite Analysis of Urinary Sediment in Detecting Bladder Cancer
RATIONALE: New diagnostic procedures such as microsatellite analysis of sediment in the urine may improve the ability to detect bladder cancer without invasive procedures.
- Trial name
- NCT00095589
- Testing
- loss of heterozygosity analysis, microarray analysis, microsatellite instability analysis
- Where
- 13 sites in United States, Canada
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer (Localized), Urinary Incontinence (C61)
Total en Bloc Urethra Preservation at Robot-assisted Prostatectomy IDEAL Stage 2a
Prospective single-arm IDEAL stage 2a feasibility study of urethra-preserving RARP in localized prostate cancer.
- Trial name
- ToP-RAP (NCT07678489)
- Testing
- ToP-RAP
- Where
- 2 sites in Germany
- Volunteers
- 60 people
- Sponsor
- Sami-Ramzi Leyh-Bannurah
Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v6 and v7
Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer
This phase I/II trial is studying the side effects of giving paclitaxel together with radiation therapy with or without trastuzumab and to see how well it works to kill any remaining tumor cells in patients who have undergone…
- Conditions
- Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v6 and v7, Stage II Bladder Cancer AJCC v6 and v7, Stage III Bladder Cancer AJCC v6 and v7
- Trial name
- NCT00238420
- Testing
- Paclitaxel, Radiation Therapy, Trastuzumab
- Where
- 184 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Cancer Harboring BRAF Alterations, HGG
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive…
- Conditions
- Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
- Trial name
- NCT05503797
- Testing
- Plixorafenib
- Where
- 70 sites in United States, Australia and 10 more
- Volunteers
- 254 people
- Sponsor
- Fore Biotherapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.